Heart Failure, Congestive Clinical Trial
Official title:
Hemodynamic Response to Exercise in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients After Upregulation of SERCA2a
Verified date | June 2022 |
Source | University of Texas Southwestern Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Heart failure with preserved ejection fraction or HFpEF, represents nearly 50% of all heart failure cases and is particularly common in the elderly. The disease has no current treatment options. Symptoms typically occur during exertion or exercise and is likely the result of increased cardiac and pulmonary congestion as a result of impaired diastolic function. Istaroxime is a novel activator of SERCA2a, an important regulator of calcium uptake within the myocyte. We will test the hypothesis that Istaroxime will improve diastolic function during exercise in HFpEF patients which in turn will reduce cardiac and pulmonary congestion.
Status | Completed |
Enrollment | 26 |
Est. completion date | December 1, 2018 |
Est. primary completion date | December 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 85 Years |
Eligibility | Healthy Senior Controls Inclusion Criteria: - age > 60 years Exclusion Criteria: - Coronary Ischemia - No chronic medical problems - BMI > 30 kg/m2 HFpEF Subjects Inclusion Criteria: - age > 60 years - signs and symptoms of heart failure - ejection fraction > 50% - objective evidence of diastolic dysfunction Exclusion Criteria: - Coronary Ischemia - Chronic Kidney Disease, stage 4 or greater - Persistent atrial fibrillation - Severe valvular disease - BMI > 45 kg/m2 |
Country | Name | City | State |
---|---|---|---|
United States | The Institute for Exercise and Environmental Medicine | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Benjamin Levine | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in cardiac filling pressures (pulmonary capillary wedge pressure) during exercise with Istaroxime | Change in cardiac filling pressures (pulmonary capillary wedge pressure) during exercise with Istaroxime | Immediate; 90 minutes after infusion | |
Secondary | Change in cardiac relaxation time (isovolumic relaxation time) during exercise with Istaroxime | Change in cardiac relaxation time (isovolumic relaxation time) during exercise | 90 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 | |
Completed |
NCT00520806 -
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
|
Phase 2/Phase 3 |